CYP2J2 Overexpression Protects against Arrhythmia Susceptibility in Cardiac Hypertrophy

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Westphal, Christina ^a   Spallek, Bastian ^b   Konkel, Anne ^a   Marko, Lajos ^b   Qadri, Fatimunnisa ^b   DeGraff, Laura M ^c   Schubert, Carola ^b   Bradbury, J Alyce ^c   Regitz Zagrosek, Vera ^b   Falck, John R ^d   Zeldin, Darryl C ^c   Müller, Dominik N ^a,b,e   Schunck, Wolf Hagen ^a   Fischer, Robert ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONNEXIN 43; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; ISOPRENALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG INFUSION; FATTY ACID SYNTHESIS; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; IN VIVO STUDY; MORTALITY; MOUSE; NONHUMAN; QRS COMPLEX; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; AORTIC VALVE STENOSIS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CARDIOMEGALY; CHRONIC DISEASE; CONNEXIN 43; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE SUSCEPTIBILITY; ELECTROPHYSIOLOGICAL PHENOMENA; ENDOMYOCARDIAL FIBROSIS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PRESSURE; RECEPTORS, ADRENERGIC, BETA; SURVIVAL ANALYSIS; VENTRICULAR REMODELING;

EID: 84883338855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073490     Document Type: Article

References (40)

1. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, et al. (2005) Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 68: 18-25.
2. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ, (2007) Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82: 50-59.
3. Nithipatikom K, Gross GJ, (2010) Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 15: 112-119.
4. Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, et al. (2004) Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res 95: e65-71.
5. Xiao YF, Huang L, Morgan JP, (1998) Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol 508 (Pt 3): 777-792.
6. Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, et al. (2004) Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol 66: 1607-1616.
7. Ke Q, Xiao YF, Bradbury JA, Graves JP, Degraff LM, et al. (2007) Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice. Mol Pharmacol 72: 1063-1073.
8. Lu T, Hoshi T, Weintraub NL, Spector AA, Lee HC, (2001) Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 537: 811-827.
9. Lee HC, Lu T, Weintraub NL, VanRollins M, Spector AA, et al. (1999) Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol 519 Pt 1: 153-168.
10. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, et al. (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272: 12551-12559.
11. Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM, (2009) Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 46: 67-74.
12. Gross GJ, Hsu A, Falck JR, Nithipatikom K, (2007) Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 42: 687-691.
13. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, et al. (2008) Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 294: H2838-2844.
14. Gross GJ, Gauthier KM, Moore J, Campbell WB, Falck JR, et al. (2009) Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog. Am J Physiol Heart Circ Physiol 297: H47-52.
15. Yu GG, Zeng XJ, Wang HX, Lu LQ, Zheng SP, et al. (2011) Cytochrome P450 2J3/epoxyeicosatrienoic acids mediate the cardioprotection induced by ischaemic post-conditioning, but not preconditioning, in the rat. Clin Exp Pharmacol Physiol 38: 63-70.
16. Gross GJ, Baker JE, Moore J, Falck JR, Nithipatikom K (2011) Abdominal Surgical Incision Induces Remote Preconditioning of Trauma (RPCT) via Activation of Bradykinin Receptors (BK2R) and the Cytochrome P450 Epoxygenase Pathway in Canine Hearts. Cardiovasc Drugs Ther.
17. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC, (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468.
18. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, et al. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95: 506-514.
19. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, et al. (2011) Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. Faseb J 25: 3436-3447.
20. Wang Y, Hill JA, (2010) Electrophysiological remodeling in heart failure. J Mol Cell Cardiol 48: 619-632.
21. Boulaksil M, Noorman M, Engelen MA, van Veen TA, Vos MA, et al. (2010) Longitudinal arrhythmogenic remodelling in a mouse model of longstanding pressure overload. Neth Heart J 18: 509-515.
22. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN, (2002) QRS duration and mortality in patients with congestive heart failure. Am Heart J 143: 1085-1091.
23. Severs NJ, Bruce AF, Dupont E, Rothery S, (2008) Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 80: 9-19.
24. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, et al. (2001) Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 88: 333-339.
25. Remo BF, Qu J, Volpicelli FM, Giovannone S, Shin D, et al. (2011) Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias. Circ Res 108: 1459-1466.
26. Jain SK, Schuessler RB, Saffitz JE, (2003) Mechanisms of delayed electrical uncoupling induced by ischemic preconditioning. Circ Res 92: 1138-1144.
27. Quindry JC, Schreiber L, Hosick P, Wrieden J, Irwin JM, et al. (2010) Mitochondrial KATP channel inhibition blunts arrhythmia protection in ischemic exercised hearts. Am J Physiol Heart Circ Physiol 299: H175-183.
28. Popp R, Brandes RP, Ott G, Busse R, Fleming I, (2002) Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 90: 800-806.
29. Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, et al. (2011) Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver Int 31: 881-890.
30. Falk RH, (2001) Atrial fibrillation. N Engl J Med 344: 1067-1078.
31. Iwasaki YK, Nishida K, Kato T, Nattel S, (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124: 2264-2274.
32. Workman AJ, (2010) Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 381: 235-249.
33. Burstein B, Nattel S, (2008) Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51: 802-809.
34. Qiu H, Li N, Liu JY, Harris TR, Hammock BD, et al. (2010) Soluble Epoxide Hydrolase Inhibitors and Heart Failure. Cardiovasc Ther 29: 99-111.
35. Xu D, Li N, He Y, Timofeyev V, Lu L, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103: 18733-18738.
36. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, et al. (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40: 529-537.
37. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, et al. (2010) Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 298: R1597-1606.
38. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA, (2002) Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 15: 167-184.
39. Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, et al. (2008) Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 51: 540-546.
40. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB, (2003) 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension 42: 555-561.